相关实验视频

Updated: Jul 12, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

升高的CANT1与肝细胞癌的预后不佳相关

Ting Liu¹, Zhi-Zhao Li², Lei Sun¹

¹Department of Pathology, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Chaoyang District, Beijing, 100015, China.

|October 19, 2023

概括

激活蛋白核酶1 (CANT1) 在肝细胞癌 (HCC) 中高度表达,与预后不佳和免疫细胞透相关. CANT1可能成为HCC治疗的潜在瘤基因和治疗点.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症基因组学癌症基因组学

背景情况:

激活蛋白核酶1 (CANT1) 是一种酶,与各种癌症有关.
它在肝细胞癌 (HCC) 中的作用和致癌机制仍未得到充分研究.
过度表达CANT1与几种瘤类型的预后不佳有关.

研究的目的:

研究CANT1在HCC中的表达,预后价值和生物功能.
探索CANT1和HCC中的瘤免疫微环境之间的关联.
分析CANT1与免疫检查点和HCC中药物敏感性的相关性.

主要方法:

使用TCGA数据库和免疫组织化学 (IHC) 分析CANT1表达的分析.
通过考克斯回归和卡普兰-梅尔曲线评估的预测值.
基因组丰富分析 (GSEA) 用于生物过程识别.
使用 ssGSEA 和 TIMER 数据库进行免疫细胞透分析.
与免疫检查点和药物敏感性的相关性分析.

主要成果:

在HCC中,CANT1的表达很高,并且与组织学等级相关.
高CANT1表达与整体生存率 (OS) 低相关,并作为独立的预后标志物.
CANT1参与细胞周期和DNA复制途径.
CANT1表达与免疫细胞透,免疫检查点和药物敏感性相关.

结论:

在HCC中,CANT1作为潜在的瘤基因起作用.
CANT1表达与瘤免疫微环境有关,包括免疫细胞和检查点.
CANT1可能代表HCC治疗的新疗法标.

关键词:

在CANT1中,CANT1可以肝细胞癌是肝细胞癌.免疫细胞的透.免疫检查站是免疫检查站预测预后预测预测

更多相关视频

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Canonical Wnt Signaling Pathway

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...